Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 5/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 5/20 | 1.00 |
| ▸ | GANC | Q8TET4 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 0.93 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.93 |
| ▸ | GBA1 | P04062 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654237 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL1479404 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265529 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265531 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL9379987 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL20466285 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7824407 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7811568 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL18271004 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL13298780 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4277988-A1 | COMPOSITIONS AND METHODS FOR TREATING FABRY DISEASE | Spark Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230364071-A1 | Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones | AMICUS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2022155665-A1 | COMPOSITIONS AND METHODS FOR TREATING FABRY DISEASE | SPARK THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220160690-A1 | Methods for Treatment of Fabry Disease | AMICUS THERAPEUTICS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220142998-A1 | Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene | AMICUS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-11241422-B2 | Methods for treatment of Fabry disease | AMICUS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031681-A1 | Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones | AMICUS THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11234972-B2 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | AMICUS THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20080056994-A1 | Assays For Diagnosing And Evaluating Treatment Options For Fabry Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2008-03-06 | — | — | US | disclosed |
| WO-2007137072-A2 | ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR FABRY DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20040242539-A1 | administering plant alkaloids such as 1-deoxy-galactonojirimycin and related compounds for prophylaxis of Fabry's disease | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2004-12-02 | — | — | US | disclosed |
| EP-1083899-A4 | METHOD OF ENHANCING LYSOSOMAL ALPHA-GALACTOSIDASE A | SINAI SCHOOL MEDICINE (US) | 2004-11-03 | — | — | EP | disclosed |
| US-6774135-B2 | 1-DEOXY-GALACTONOJIRIMYCIN AND RELATED COMPOUNDS USED TO TREAT FABRY DISEASE | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2004-08-10 | — | — | US | disclosed |
| US-20020156100-A1 | 1-deoxy-galactonojirimycin and related compounds used to treat fabry disease | MOUNT SINAI SCHOOL OF MEDICINE | 2002-10-24 | — | — | US | disclosed |
| US-20010018090-A1 | Calorie reducing agent | TOYOTAMA HEALTHY FOODS CO., LTD. (JP) | 2001-08-30 | — | — | US | disclosed |
| US-6274597-B1 | ADMINISTERING 1-DEOXYGALACTONOJIRIMYCIN AND RELATED COMPOUNDS TO TREAT FABRY DISEASE | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| EP-1083899-A1 | METHOD OF ENHANCING LYSOSOMAL $g(a)-GALACTOSIDASE A | Fan, Jian-Qiang (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062517-A1 | METHOD OF ENHANCING LYSOSOMAL α-GALACTOSIDASE A | FAN JIAN QIANG (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142998-A1 | Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene | GAA, GLA, GBA1 | MGAM 61/4885FUCA1 136/4885GLA 2/4885 |
| US-11241422-B2 | Methods for treatment of Fabry disease | GAA, HSP90B1, GBA1 | MGAM 421/4885FUCA1 118/4885GLA 17/4885 |
| US-20080056994-A1 | Assays For Diagnosing And Evaluating Treatment Options For Fabry Disease | GAA, GBA1, MAN2B1 | MGAM 295/4885FUCA1 156/4885GLA 26/4885 |
| US-20220160690-A1 | Methods for Treatment of Fabry Disease | GAA, HSP90B1, GBA1 | MGAM 421/4885FUCA1 118/4885GLA 17/4885 |
| US-20040242539-A1 | administering plant alkaloids such as 1-deoxy-galactonojirimycin and related compounds for prophylaxis of Fabry's disease | GAA, GALC, MAN2B1 | MGAM 42/4885FUCA1 22/4885GLA 5/4885 |
| US-20020156100-A1 | 1-deoxy-galactonojirimycin and related compounds used to treat fabry disease | GAA, GALC, GLA | MGAM 16/4885FUCA1 38/4885GLA 3/4885 |
| US-11234972-B2 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | GAA, GLA, GBA1 | MGAM 61/4885FUCA1 136/4885GLA 2/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | MGAM 25/4885FUCA1 15/4885GLA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.